Table 1.
Mendelian randomization analysis on metabolites, lipids and proteins against incident type 2 diabetes
| Metabolites | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| variable | method | nsnp | Beta | Lower | Upper | P-value | Egger intercept | Q | Q(df) | Q(P-value) |
| AADA | IVW | 2 | 0.02 | -0.09 | 0.13 | 0.77 | 0.02 | 1 | 0.88 | |
| Citrulline | IVW | 6 | -0.01 | -0.29 | 0.28 | 0.97 | -0.04 | 83.02 | 5 | 1.95·10-16 |
| Isoleucine | IVW | 5 | -0.06 | -0.94 | 0.83 | 0.90 | -0.11 | 127.69 | 4 | 1.22·10-26 |
| Leucine | IVW | 6 | -0.08 | -0.74 | 0.58 | 0.81 | -0.07 | 127.77 | 5 | 7.09·10-26 |
| Lipids | ||||||||||
| variable | method | nsnp | Beta | Lower | Upper | P-value | Egger intercept | Q | Q(df) | Q(P-value) |
| PE 18:0;0_18:2;0 | IVW | 3 | -0.07 | -0.12 | -0.02 | 3.89·10-3 | 0.02 | 5.53 | 2 | 0.06 |
| SM 42:2;2 | IVW | 2 | 0.00 | -0.07 | 0.07 | 0.99 | 0.91 | 1 | 0.34 | |
| TAG 50:1;0 | IVW | 2 | 0.01 | -0.04 | 0.05 | 0.75 | 0.00 | 1 | 0.97 | |
| Proteins | ||||||||||
| variable | method | nsnp | Beta | Lower | Upper | P-value | Egger intercept | Q | Q(df) | Q(P-value) |
| GDF15 | IVW | 8 | 0.03 | 0.01 | 0.05 | 2.68·10-3 | 0.01 | 8.83 | 7 | 0.27 |
| IL-18Ra | IVW | 14 | 0.02 | 0.003 | 0.03 | 0.01 | 0.00 | 6.75 | 13 | 0.91 |
| FAS | IVW | 4 | 0.05 | 0.005 | 0.09 | 0.03 | 0.00 | 6.34 | 3 | 0.10 |
| RTN4R | IVW | 10 | -0.01 | -0.03 | 0.01 | 0.28 | -0.01 | 4.16 | 9 | 0.90 |
| ENPP7 | IVW | 4 | 0.01 | -0.01 | 0.02 | 0.34 | 0.00 | 0.85 | 3 | 0.84 |
| CRELD1 | IVW | 7 | 0.01 | -0.01 | 0.02 | 0.43 | 0.01 | 7.33 | 6 | 0.29 |
IVW inverse variance weighting, nsnp, number of instruments. Statistical test MR: Inverse variance weighted regression; statistical test heterogeneity: Cohran’s Q test.